Pfizer's posts $4.9B 1Q profit as vaccine strategy pays off
Selling vaccines during a pandemic has boosted Pfizer's bottom line and proven that a strategy it embarked upon over a decade ago is now paying off handsomely. |!| Elko
Selling vaccines during a pandemic has boosted Pfizer's bottom line and proven that a strategy it embarked upon over a decade ago is now paying off handsomely. |!| Elko